高危胚胎性脑肿瘤幼儿大剂量甲氨蝶呤的3期随机试验
ACNS0334是一项3期随机研究,评估大剂量甲氨蝶呤用于<36个月新诊断高危胚胎性脑肿瘤患儿。主要终点为治疗结束时完全缓解(CR),59例可评估患者中28例(47.5%)达CR,甲氨蝶呤组15/30(50%)对比无甲氨蝶呤组13/29(45%)(P=0.35)。髓母细胞瘤(MB)亚组CR为甲氨蝶呤组12/19(63%)对比无甲氨蝶呤组6/20(30%)(P=0.039),Group 3 MB的5年无事件生存(EFS)甲氨蝶呤组70%(90%CI: 39.6-87.2)对比无甲氨蝶呤组33.3%(90%CI: 15.0-52.9)(P=0.037),其他诊断未见获益。
要点
- 大剂量甲氨蝶呤改善高危Group 3 MB幼儿的CR和EFS
- 其他胚胎性肿瘤亚型未见甲氨蝶呤获益
- 所有SHH MB(n=11)均为生存者
核心结论
- 在强化化疗中加入甲氨蝶呤改善了高危Group 3 MB幼儿的CR和EFS,但其他诊断未见获益。
研究设计与样本
- ACNS0334为3期随机研究,纳入<36个月新诊断高危胚胎性脑肿瘤患儿,治疗包括3周期诱导化疗(含或不含甲氨蝶呤)后3周期大剂量巩固化疗联合造血干细胞输注。
- 主要终点为治疗结束时完全缓解(CR),次要终点包括组间及与历史对照的EFS比较,分子特征回顾性分析,显著性检验为单侧。
主要发现
- 77例合格患者中59例可评估疗效,28例(47.5%)达CR,甲氨蝶呤组15/30(50%)对比无甲氨蝶呤组13/29(45%)(P=0.35)。
- MB亚组CR为甲氨蝶呤组12/19(63%)对比无甲氨蝶呤组6/20(30%)(P=0.039)。
- Group 3 MB的5年EFS为甲氨蝶呤组70%(90%CI: 39.6-87.2)对比无甲氨蝶呤组33.3%(90%CI: 15.0-52.9)(P=0.037)。
- 其他胚胎性肿瘤CR为甲氨蝶呤组3/11(27%)对比无甲氨蝶呤组7/9(78%)(P=0.99)。
- 多层菊形团胚胎性肿瘤(n=14)EFS为甲氨蝶呤组20.0%(90%CI: 1.8-52.5)对比无甲氨蝶呤组33.3%(90%CI: 10.8-58.1)(P=0.58);松果体母细胞瘤(n=9)EFS为甲氨蝶呤组16.7%(90%CI: 1.6-46.1)对比无甲氨蝶呤组0%(P=0.52)。
关键数值与推荐
- CR定义:治疗结束时完全缓解。
- Group 3 MB的5年EFS:甲氨蝶呤组70%(90%CI: 39.6-87.2),无甲氨蝶呤组33.3%(90%CI: 15.0-52.9),P=0.037。
- MB亚组CR:甲氨蝶呤组12/19(63%)对比无甲氨蝶呤组6/20(30%),P=0.039。
临床怎么用
- 对于<36个月高危Group 3 MB幼儿,可考虑在强化化疗中加入大剂量甲氨蝶呤以改善CR和EFS。
- 其他胚胎性肿瘤亚型(如ETMR、松果体母细胞瘤)未显示甲氨蝶呤获益,需个体化决策。
局限性
- 分子特征为回顾性分析。
- 部分亚组样本量小。
- 显著性检验为单侧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Embryonal brain tumors are the leading cause of cancer death in young children. METHODS: ACNS0334 was a phase 3 randomized study evaluating high-dose methotrexate in young children < 36 months old with newly diagnosed high-risk embryonal brain tumors. Treatment included 3 cycles of induction chemotherapy with or without methotrexate followed by 3 cycles of high-dose consolidation chemotherapy with hematopoietic stem-cell infusion. Primary endpoint was complete response (CR) at the end of therapy. Secondary endpoints included a comparison of event-free survival (EFS) between arms and to historical controls. Molecular characterization was conducted retrospectively. Tests of significance were one-sided. RESULTS: Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR, 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P = 0.35). For MB, CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P = 0.039). Considering molecular diagnosis, all SHH MB (n = 11) were survivors. Five-year EFS was 70% (90% CI: 39.6-87.2) for 10 Group 3 MB with methotrexate versus 33.3% (90% CI: 15.0-52.9) for 15 without (P = 0.037). In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P = 0.99). No benefit with methotrexate was observed for Embryonal Tumor with Multilayered Rosettes (n = 14, EFS 20.0% [90% CI: 1.8-52.5] with methotrexate versus 33.3% [90% CI: 10.8-58.1] without, P = 0.58), or pineoblastoma (n = 9, EFS 16.7% [90% CI: 1.6-46.1] with methotrexate versus 0% without, P = 0.52). CONCLUSIONS: The addition of methotrexate to intensive chemotherapy improved CR and EFS for young children with high-risk Group 3 MB, but not other diagnoses.
引用
- Mazewski C, Leary SES, Kang G, et al. Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group. Neuro Oncol. 2025. PMID: 40485042. doi:10.1093/neuonc/noaf132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。